Prerana Jha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11671384/publications.pdf

Version: 2024-02-01

36	916	394421	454955
papers	citations	19 h-index	30 g-index

36	36	36	1684
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene expression based profiling of pleomorphic xanthoastrocytoma highlights two prognostic subgroups.. American Journal of Translational Research (discontinued), 2022, 14, 1010-1023.	0.0	0
2	Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 410-417.	1.2	2
3	Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?. Neurological Sciences, 2021, 42, 925-934.	1.9	10
4	Mutational Spectrum of CAPN3 with Genotype-Phenotype Correlations in Limb Girdle Muscular Dystrophy Type 2A/R1 (LGMD2A/LGMDR1) Patients in India. Journal of Neuromuscular Diseases, 2021, 8, 125-136.	2.6	3
5	Analysis of PDâ€L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology, 2019, 39, 413-424.	1.2	14
6	Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescenceÂin-situ hybridization in resource constrained centres. Journal of Neuro-Oncology, 2019, 143, 393-403.	2.9	16
7	PATH-65. MOLECULAR SIGNATURE OF FAT1 RELATED MOLECULES IN GLIOMAS IN THE CONTEXT OF THE WHO 2016 CLASSIFICATION. Neuro-Oncology, 2019, 21, vi158-vi158.	1.2	0
8	MBRS-55. MOLECULAR CLASSIFICATION OF MEDULLOBLASTOMAS: NANOSTRING nCOUNTER ASSAY VS A COMBINATION OF IMMUNOHISTOCHEMISTRY AND FLUORESCENCE IN-SITU HYBRIDISATION. Neuro-Oncology, 2018, 20, i140-i140.	1.2	0
9	ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. Brain Pathology, 2017, 27, 138-145.	4.1	16
10	Pediatric High Grade Glioma. Current Cancer Research, 2017, , 241-266.	0.2	1
11	Genetic alterations related to <scp>BRAFâ€FGFR</scp> genes and dysregulated <scp>MAPK/ERK</scp>/m<scp>TOR</scp> signaling in adult pilocytic astrocytoma. Brain Pathology, 2017, 27, 580-589.	4.1	26
12	Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India. Translational Oncology, 2016, 9, 371-376.	3.7	11
13	Expression of DNA methyltransferases 1 and 3B correlates with EZH2 and this 3-marker epigenetic signature predicts outcome in glioblastomas. Experimental and Molecular Pathology, 2016, 100, 312-320.	2.1	23
14	A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India. Brain Tumor Pathology, 2016, 33, 183-190.	1.7	7
15	<scp>EZH2</scp> expression in gliomas: Correlation with <scp>CDKN2A</scp> gene deletion/ p16 loss and <scp>MIB</scp>â€1 proliferation index. Neuropathology, 2015, 35, 421-431.	1.2	19
16	Genomeâ€wide small noncoding <scp>RNA</scp> profiling of pediatric highâ€grade gliomas reveals deregulation of several mi<scp>RNA</scp>s, identifies downregulation of sno<scp>RNA</scp> cluster <scp>HBII</scp>â€52 and delineates <scp>H3F3A</scp> and TP53 mutantâ€specific mi<scp>RNA</scp>s and sno<scp>RNA</scp>s. International Journal of Cancer, 2015, 137, 2343-2353.	5.1	36
17	GENO-31MOLECULAR GENETIC PROFILE OF ADULT PILOCYTIC ASTROCYTOMA: BRAF-FGFR GENOMIC ALTERATIONS AND ACTIVATION OF MAPK/ERK/mTOR PATHWAY. Neuro-Oncology, 2015, 17, v98.3-v98.	1.2	0
18	Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genetics, 2015, 208, 91-95.	0.4	29

#	Article	IF	Citations
19	Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. Journal of Neuro-Oncology, 2015, 121, 489-497.	2.9	49
20	Meningeal hemangiopericytomas: A clinicopathological study with emphasis on <scp>MGMT</scp> (<scp>O⁶</scp>â€methylguanineâ€<scp>DNA</scp> methyltransferase) promoter methylation status. Neuropathology, 2014, 34, 333-342.	1.2	2
21	Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro-Oncology, 2014, 16, 1607-1617.	1.2	32
22	Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers. Biology Direct, 2013, 8, 10.	4.6	69
23	Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro-Oncology, 2013, 15, 718-726.	1.2	101
24	<scp>CDKN2A</scp> deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Neuropathology, 2013, 33, 405-412.	1.2	51
25	A study of clinicoâ€pathological parameters and O⁶ â€“ methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. Neuropathology, 2012, 32, 534-542.	1.2	31
26	A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. Journal of Clinical Neuroscience, 2011, 18, 66-70.	1.5	59
27	IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Experimental and Molecular Pathology, 2011, 91, 385-393.	2.1	34
28	Molecular profile of oligodendrogliomas in young patients. Neuro-Oncology, 2011, 13, 1099-1106.	1.2	43
29	Detection of Allelic Status of 1p and 19q by Microsatellite-based PCR Versus FISH. Diagnostic Molecular Pathology, 2011, 20, 40-47.	2.1	28
30	Characterization of Molecular Genetic Alterations in GBMs Highlights a Distinctive Molecular Profile in Young Adults. Diagnostic Molecular Pathology, 2011, 20, 225-232.	2.1	43
31	O ⁶ -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status. Neurology India, 2011, 59, 229.	0.4	17
32	Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients. Neurology India, 2011, 59, 254.	0.4	20
33	O 6-Methylguanine DNA Methyltransferase Gene Promoter Methylation Status in Gliomas and Its Correlation With Other Molecular Alterations: First Indian Report With Review of Challenges for Use in Customized Treatment. Neurosurgery, 2010, 67, 1681-1691.	1.1	40
34	MGMT gene promoter methylation in pediatric glioblastomas. Child's Nervous System, 2010, 26, 1613-1618.	1.1	38
35	Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genetics and Cytogenetics, 2010, 198, 126-134.	1.0	9
36	Limb girdle muscular dystrophy type 2A in India: A study based on semi-quantitative protein analysis, with clinical and histopathological correlation. Neurology India, 2010, 58, 549.	0.4	37